Difference between revisions of "Axitinib (Inlyta)"
m |
m |
||
| Line 23: | Line 23: | ||
*5/14/2019: Approved in combination with [[Avelumab (Bavencio)|avelumab]] for first-line treatment of patients with advanced [[Renal cell carcinoma|renal cell carcinoma (RCC)]]. ''(Approval extended to first-line setting, in combination; based on JAVELIN Renal 101)'' | *5/14/2019: Approved in combination with [[Avelumab (Bavencio)|avelumab]] for first-line treatment of patients with advanced [[Renal cell carcinoma|renal cell carcinoma (RCC)]]. ''(Approval extended to first-line setting, in combination; based on JAVELIN Renal 101)'' | ||
*6/4/2020: Approved in combination with pembrolizumab, for the first-line treatment of patients with advanced [[Renal cell carcinoma|RCC]]. ''(Based on KEYNOTE-426)'' | *6/4/2020: Approved in combination with pembrolizumab, for the first-line treatment of patients with advanced [[Renal cell carcinoma|RCC]]. ''(Based on KEYNOTE-426)'' | ||
| + | |||
| + | ==History of changes in EMA indication== | ||
| + | *9/3/2012: Initial marketing authorization as Inlyta. | ||
==Also known as== | ==Also known as== | ||
*'''Code names:''' AG013736, AG-013736 | *'''Code names:''' AG013736, AG-013736 | ||
| − | *'''Brand name:''' Inlyta | + | *'''Brand name:''' Axishil, Axpero, Inlybest, Inlyta, Luciax |
==References== | ==References== | ||
| Line 44: | Line 47: | ||
[[Category:Medullary thyroid cancer medications]] | [[Category:Medullary thyroid cancer medications]] | ||
| + | [[Category:EMA approved in 2012]] | ||
[[Category:FDA approved in 2012]] | [[Category:FDA approved in 2012]] | ||
Revision as of 01:39, 5 December 2021
General information
Class/mechanism: Tyrosine kinase inhibitor of vascular endothelial growth factor receptors VEGFR-1, VEGFR-2, and VEGFR-3, which interferes with tumor angiogenesis, growth, and cancer progression, at picomolar concentrations. Inhibits PDGFRA, PDGFRB and c-kit at nanomolar concentrations.[1][2][3][4]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Inlyta Side Effect Tips & Videos (Pfizer)[5]
- Axitinib (Inlyta) package insert[1]
- Axitinib (Inlyta) patient drug information (Chemocare)[6]
- Axitinib (Inlyta) patient drug information (UpToDate)[7]
History of changes in FDA indication
- 1/27/2012: Initial approval for the treatment of advanced renal cell carcinoma after failure of one prior systemic therapy. (Based on AXIS)
- 5/14/2019: Approved in combination with avelumab for first-line treatment of patients with advanced renal cell carcinoma (RCC). (Approval extended to first-line setting, in combination; based on JAVELIN Renal 101)
- 6/4/2020: Approved in combination with pembrolizumab, for the first-line treatment of patients with advanced RCC. (Based on KEYNOTE-426)
History of changes in EMA indication
- 9/3/2012: Initial marketing authorization as Inlyta.
Also known as
- Code names: AG013736, AG-013736
- Brand name: Axishil, Axpero, Inlybest, Inlyta, Luciax
References
- ↑ 1.0 1.1 1.2 Axitinib (Inlyta) package insert
- ↑ Axitinib (Inlyta) package insert (locally hosted backup)
- ↑ Inlyta manufacturer's website
- ↑ Matthew Stenger. What You Need to Know About Axitinib, New Agent for Treating Advanced Renal Cell Carcinoma. ASCO Post, March 15, 2012, Volume 3, Issue 5.
- ↑ Inlyta Side Effect Tips & Videos (Pfizer)
- ↑ Axitinib (Inlyta) patient drug information (Chemocare)
- ↑ Axitinib (Inlyta) patient drug information (UpToDate)